Reducing cardiac deaths with hypolipidemic drugs.
Naito
H K
HK
Department of Biochemistry, Cleveland Clinic Foundation, OH 44106.
D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D003084:Colestipol / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D005247:Feeding Behavior; D015248:Gemfibrozil; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000178:diet therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D009525:Niacin / Q000627:therapeutic use; D010353:Patient Education as Topic; D010421:Pentanoic Acids / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D008055:Lipids; D008077:Lipoproteins, LDL; D010421:Pentanoic Acids; D002792:Cholestyramine Resin; D009525:Niacin; D002784:Cholesterol; D002994:Clofibrate; D003084:Colestipol; D011341:Probucol; D015248:Gemfibrozil